Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SS202
- Development stage
- Preclinical
- Lead developer
- Betta Pharmaceuticals
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
SS202 is an ultra-long-acting recombinant human growth hormone (somatropin) candidate drug designed for once-monthly administration. It is being developed for the treatment of pediatric and adult growth hormone deficiency (GHD), idiopathic short stature, and Turner syndrome. SS202 utilizes an innovative dual long-acting technology platform that combines Fc fusion and fatty acid conjugation to extend systemic exposure and reduce the injection burden compared to daily or weekly recombinant growth hormone therapies. In October 2026, Betta Pharmaceuticals acquired the global exclusive rights to the SS202 project from Hangzhou Shengsi Biopharmaceuticals (Gensciences).
02
Targets
GHR (Growth hormone receptor)
Beyond the preview
Go deeper on SS202.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SS202.